Navigation Links
Simcere Pharmaceutical Group Seeking Approval to Manufacture and Sell Influenza Drug zanamivir
Date:5/6/2009

NANJING, China, May 6 /PRNewswire-Asia/ -- Simcere Pharmaceutical Group (NYSE: SCR), a leading manufacturer and supplier of branded generic and innovative anti-cancer pharmaceuticals in China, announced today that the Company is seeking approval to manufacture and sell products containing zanamivir, one of only two WHO approved drugs to which the new H1N1 strain of influenza A has been shown to be susceptible.

GlaxoSmithKline granted a license to Simcere in 2006 to make products containing zanamivir. Simcere is the only pharmaceutical company in mainland China that has such a license.

"We look forward to obtaining the approval to manufacture and sell zanamivir in China. To this end, we have already begun to prepare the raw materials and manufacturing facilities required to launch this drug," commented Mr. Xiaojin Yin, Senior Vice President of Research and Development of Simcere Pharmaceutical Group.

About Simcere Pharmaceutical Group

Simcere Pharmaceutical Group (NYSE: SCR, Simcere) is a leading manufacturer and supplier of branded generic and innovative pharmaceuticals in China. In recent years, Simcere has been focusing its strategy on the development of innovative pharmaceuticals and first-to-market generics, and has introduced an innovative anti-cancer medication Endu, a first-to-market medication Sinofuan, and first-to-market generics such as Bicun and Anxin. Simcere manufactures and sells antibiotics, anti-cancer medication and stroke management medication. Simcere concentrates its research and development efforts on the treatment of diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective pharmacotherapy such as cancer, strokes, orthopaedics and infectious diseases. For more information about Simcere Pharmaceutical Group, please visit http://www.simcere.com .


'/>"/>
SOURCE Simcere Pharmaceutical Group
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Simcere Pharmaceutical Group Acquires a 51% Stake in Boda Pharmaceutical Co., Ltd.
2. Simcere Pharmaceutical Group Reports Third Quarter 2007 Results
3. Simcere Pharmaceutical Group to Announce Fourth Quarter 2007 Earnings on Tuesday, March 4, 2008
4. Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2007 Results
5. Simcere Pharmaceutical Group Announces Participation in Brean Murray Carret & Co.s Fourth Investor Tour of China
6. Simcere Pharmaceutical Group to Announce First Quarter 2008 Earnings on Tuesday, May 6, 2008
7. Simcere Pharmaceutical Group Acquires 70% Stake in Wuhu Zhong Ren Pharmaceutical Co. Ltd.
8. Simcere Pharmaceutical Group Announces SFDA Approval of First-to-Market Generic Biapenem Injection Anxin
9. Simcere Pharmaceutical Group Reports Unaudited Second Quarter 2008 Results
10. Simcere Pharmaceutical Group to Participate in Goldman Sachs China Investment Frontier Conference 2008
11. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... ... February 22, 2017 , ... Secure ... to the largest network of hospitals, health information exchanges, physicians and patients, announced ... Information Technology (ONC-HIT) 2015 Edition Health IT Module Certification via Drummond Group LLC, ...
(Date:2/22/2017)... , ... February 22, 2017 , ... ... with chronic conditions reported skipping doses or not filling a prescription because they ... under-insured, rates of cost-related problems getting medications were 30-60%*. At the ...
(Date:2/22/2017)... ... ... Using the power of the internet, IdrisArkette.com has managed to produce more ... just 24 months, thousands of individuals interested in a medical procedure managed to be ... is not getting quieter. In fact it’s becoming noisier by the day. If you ...
(Date:2/22/2017)... ... February 22, 2017 , ... Bellus Medical, a ... innovation in the delivery of Platelet Rich Plasma (PRP). PRP systems are used ... to accelerate tissue synthesis and provide a faster and more efficient healing process. ...
(Date:2/22/2017)... ... ... Super-Sod will attend the Athens Home Show with a brand new look ... Super-Sod’s simple Athens Home Show booth of 2016, this year’s exhibit space includes recycled ... Roquemore constructed furniture from recycled pallet wood at the Super-Sod farm in Fort Valley, ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... CAMBRIDGE, England and DEERFIELD, Ill. ... U.S.A. , Inc., a wholly-owned subsidiary ... Limited, a joint venture between Cambridge Cognition Holdings PLC ... the use of a specially designed app on an ... in patients with Major Depressive Disorder (MDD). ...
(Date:2/23/2017)... , Feb. 22, 2017 Mixed tocopherols market ... The mixed tocopherols market is projected to reach USD 5.27 ... The market is driven by factors such as health and ... and in feed, and regulations for sourcing, processing, packaging, and ... tocopherols from emerging markets such as the Asia-Pacific ...
(Date:2/23/2017)... 23, 2017 - For Every ,Count, Shire ... ... Open to All at http://www.shire.com/RareCount   Shire plc ... of ,Rare Count, in honor of Rare Disease Day and the ... nearly one in 20 global citizens. It is estimated that 50% ...
Breaking Medicine Technology: